Objectives: Secondary prevention trials in subjects with preclinical Alzheimer disease may require documentation of brain amyloidosis. The identification of inexpensive and noninvasive screening variables that can identify individuals who have significant amyloid accumulation would reduce screening costs.
Alzheimer disease (AD) pathophysiology is thought to begin decades before the emergence of overt clinical symptoms. [1] [2] [3] The many failed treatment trials among patients with AD dementia, despite reducing brain amyloid levels in some studies, highlight the importance of the preclinical phase of AD for the development of disease-modifying therapies. 4 As amyloid pathology appears to be the first pathologic entity necessary for the development of AD that is detectable by currently available biomarkers, [5] [6] [7] [8] the identification of amyloid-positive individuals is critical for drug development. Secondary AD prevention trials in preclinical subjects are now being designed and some of these trials, especially those with an anti-amyloid mechanistic target, require documentation of brain amyloidosis for enrollment. While the exact proportion of amyloid-positive cognitively normal (CN) individuals depends on the age and genetic background of the cohort, it is estimated that approximately 20%-40% of elderly individuals will have brain amyloidosis. 9 -11 It is not optimally efficient in terms of cost, time, and manpower to screen an entire population with amyloid imaging or a lumbar puncture for CSF amyloid-␤ to identify eligible individuals with brain amyloidosis. Thus, the aim of the present study was to examine the utility of inexpensive and easily available screening variables including demographic, family history, cognitive performance (domain-specific and self-reported), and APOE genotype to predict amyloid positivity in a population-based cohort of CN individuals. We further sought to estimate and compare the sample size needed to screen for therapeutic trials with and without the addition of these potential predictors.
METHODS Subjects. The Mayo Clinic Study of Aging (MCSA) is a population-based study of cognitive aging that was established in Olmsted County, Minnesota, in October 2004. Details of the study design and participant recruitment are provided elsewhere. 12, 13 All MCSA subjects undergo a clinical and cognitive assessment every 15 months that includes 9 neuropsychological tests. Beginning in 2006, both newly and previously enrolled subjects were offered the opportunity to undergo PET imaging. Severe illness was the only exclusion criterion for participating in imaging. Subjects were not excluded due to neurologic, psychiatric, or systemic illnesses to preserve the representativeness of the study sample. The evaluations of all subjects were reviewed by a consensus panel consisting of behavioral neurologists, geriatricians, neuropsychologists, and study nurses. Subjects were diagnosed by the consensus panel as being CN based on the clinical assessments including mental status examinations, informant interviews, and the neuropsychological testing battery described below. Imaging findings were not used in forming a clinical diagnosis.
Standard protocol approvals, registrations, and patient consents.
The study protocols were approved by the Mayo Clinic and Olmsted Medical Center Institutional Review Boards. All subjects provided signed informed consent to participate in the study and in the imaging protocols.
Neuropsychological testing. The neuropsychological battery was constructed as previously described. 12, 13 Domainspecific measures were formulated from the Wechsler Adult Intelligence Scale-Revised (WAIS-R), Wechsler Memory Scale-Revised (WMS-R), Auditory Verbal Learning Test (AVLT), Trail Making Test (TMT), category fluency test, and Boston Naming Test (BNT). Four cognitive domains were assessed: executive (TMT: Part B, WAIS-R Digit Symbol); language (BNT, category fluency); memory (WMS-R Logical Memory-II delayed recall, WMS-R Visual Reproduction-II delayed recall, AVLT delayed recall); and visuospatial (WAIS-R Picture Completion, WAIS-R Block Design). Individual test scores were first converted to z scores using the mean and SD from the MCSA 2004 enrollment cohort. The individual z scores were averaged to create 4 domain-specific z scores. A global cognitive summary score was formed from the average of the 4 domain z scores and then converted to a z score by subtracting the mean and dividing by the SD.
The measurement of subjective memory complaints was adapted from the first 5 questions on the Blessed Memory Test. Questions 1-4 were given a score of 2 if subjects reported "definitely worse than when I was younger," 1 if they were "slightly worse," and 0 if they were "as good or better." Item 5 (problems remembering appointments correctly) was scored 1 for yes and 0 for no. Questions 1-5 were summed for a score ranging from 0 (no concern) to 9 (highest concern). Imaging methods. PET images 14 were acquired using a PET/CT scanner (DRX, GE Healthcare). A CT image was obtained for attenuation correction. The 11 C Pittsburgh compound B (PiB)-PET scan, consisting of 4 5-minute dynamic frames, was acquired from 40 to 60 minutes after injection. 15, 16 Quantitative image analysis for PiB was done using our in-house fully automated image processing pipeline. 10 A cortical PiB-PET retention ratio was formed by calculating the median uptake over voxels in the prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, and posterior cingulate/precuneus regions of interest (ROIs) for each subject and dividing this by the median uptake over voxels in the cerebellar gray matter ROI of the atlas. 17 The atlas and image registration steps were based on a 3D T1-weighted volume MRI sequence. We have previously shown in this cohort that 90% diagnostic sensitivity for clinically diagnosed AD dementia corresponds to a PiB-PET cutpoint of 1.5, 18 and therefore included this cutpoint as our outcome. However, as a lower amyloid PiB-PET cutpoint may be better suited to answer the question of amyloid positivity in CN subjects who are earlier in the disease pathway, we also examined predictors of a PiB-PET cutpoint of 1.4.
Statistical methods. Differences in variables between those
with and without PiB-PET scans were evaluated using Wilcoxon rank sum test and 2 tests. Logistic regression models were used to assess predictors of PiB positivity (PiB retention ratio Ͼ1.4 or Ͼ1.5) in univariate and multivariate models after adjustment for other covariates. Four multivariate models were fit, each building upon the previous model. The models were structured to reflect the ease with which different categories of predictive information can be acquired (i.e., each model is built to reflect the time and effort burden needed to collect data from study participants). As such, the first model included only predictors that could be easily obtained without patient contact (age and sex), the second model would require a phone call (family history of dementia and subjective memory complaint), the third model would require the patient to have a blood draw (APOE genotype), and the final model included predictors that would require the subject to undergo an extensive neuropsychological battery (global z score). Our goal was not to find "the best" multivariable model, but to fit and summarize a prescribed series of models based on increasing patient burden.
We used the area under the receiver operating characteristic curve (AUROC) from the models as a measure of how well the model discriminated between PiB-positive and -negative subjects. The multivariate logistic models allowed us to assign a predicted probability of being PiB-positive to each subject based on values for the variables in the model. Using these estimated probabilities, we defined those with probabilities Ͼ0.50 as being more likely to be PiB-positive and those with probabilities Յ0.50 as more likely to be PiB-negative. The positive predictive value (PPV) of the model was then calculated as the percent of true PiB positives, as identified from the PiB scan, out of the total number of subjects who were identified as likely to be PiBpositive from the model. Similarly, the negative predictive value (NPV) was calculated as the percent of true PiB negatives out of the total number of subjects who were identified as likely to be PiB-negative from the model. For each characteristic, we also estimated the number needed to screen to enroll 100 participants with PiB Ͼ1.4 or Ͼ1.5 into a clinical trial by age group (70 -79 and 80 -89 years). The number needed to screen was based on the proportions of the characteristics in the MCSA data.
RESULTS
The characteristics of the 483 CN individuals with a PiB-PET scan are shown in table 1. The median age of the sample was 78 years (interquartile range [IQR] 75, 82) and 55% were male. The median Mini-Mental State Examination (MMSE) score was 28 (IQR 27, 29) and global z score was 0.68 (IQR ϭ 0.13, 1.24). There were 124 individuals (26%) with a family history of dementia, 122 (25%) had at least 1 APOE 4 allele, 211 (44%) had PiB Ͼ 1.4, and 151 (31%) had PiB Ͼ1.5. Compared to the other CN MCSA participants enrolled in the study but without a PiB-PET scan, those with a scan (included in this analysis) were significantly ( p Ͻ 0.05) younger (78 vs 80 years), more frequently men (55% vs 49%), and performed slightly better on the MMSE, global cognition, and each of the 4 cognitive domains (table 1) .
The relative odds of PiB Ͼ1.4 and Ͼ1.5 are shown in table 2 for the individual effects of age, sex, APOE genotype, family history, cognitive tests, and domain z scores. Participants with an APOE 4 allele had greater odds of PiB Ͼ1.4 (odds ratio [OR] 3.04, 95% confidence interval [CI] 1.98 -4.66) and PiB Ͼ1.5 (OR 3.16, 95% CI 2.06 -4.85). Older age and a family history of dementia/AD were also associated with elevated odds of PiB Ͼ1.4 and Ͼ1.5, while better cognitive performance across all domains and tests was associated with reduced odds. In univariate (table 3) . However, the PPV of this model was 57%, an increase from the baseline rate of 44% with PiB Ͼ1.4. The addition of family history of dementia/AD and subjective memory complaints (model 2) slightly increased the AUROC and reduced the PPV and NPV. Adding information about the presence of an APOE 4 allele (model 3) appreciably increased the model discrimination (AUROC ϭ 0.70; PPV ϭ 62%; NPV ϭ 66%). The addition of global z score performance (model 4) did not improve the overall model for discrimination, PPV, or NPV.
For the prediction of PiB Ͼ1.5, age and sex (model 1, table 4) again provided only fair discrimination (AUROC ϭ 0.61) for identifying PiBpositive individuals. However, the PPV of this model was 50%, an increase from the baseline rate of 31% in this population. Information concerning family history of dementia/AD and subjective memory complaints (model 2) slightly increased the discrimination of PiB Ͼ1.5 (AUROC ϭ 0.64) and greatly increased the PPV (67%). The addition of information on APOE genotype (model 3) and global z score performance (model 4) further increased the discrim- Abbreviations: AD ϭ Alzheimer disease; AUROC ϭ area under the receiver operating characteristic curve; CI ϭ confidence interval; NPV ϭ negative predictive value; OR ϭ odds ratio; PPV ϭ positive predictive value. ination, but the AUROC value (0.71) for model 4 remained modest. In additional analyses, we substituted domain-specific z scores, the AVLT, and MMSE for the global z score, but they did not improve model prediction or discrimination (data not shown).
We also estimated the number needed to screen to enroll 100 individuals with PiB Ͼ1.4 or Ͼ1.5, based on the prevalence of each characteristic in the MCSA and stratified by age group (70 -79 vs 80 -89). The predictability of multiple factors varied with age and PiB cutoff (table 5) . For example, screening on APOE genotype alone reduced the number needed to screen to enroll 100 participants with PiB Ͼ1.5 by 48% in persons aged 70 -79 and 33% in those aged 80 -89. To enroll 100 participants with PiB Ͼ1.4, screening on APOE genotype reduced the number needed to screen by 37% in persons aged 70 -79 and 32% in persons aged 80 -89. There was some difference by age for subjective memory complaints with PiB Ͼ1.4. However, for PiB Ͼ1.5, screening individuals with memory complaints reduced the number needed to screen to enroll 100 participants by 37% for persons aged 70 -79, and by only 10% for persons aged 80 -89. Finally, the effect of sex varied by age for both cutpoints such that men aged 70 -79, and women aged 80 -89, were more likely to be PiB positive.
DISCUSSION
In this study, we examined indicators of PiB positivity (defined as either PiB retention ratio Ͼ1.4 or Ͼ1.5) among 483 individuals enrolled in the population-based MCSA. Information on age, sex, APOE genotype, family history of dementia, and subjective memory complaints, all easily obtainable information with little participant burden, would greatly reduce costs of screening the population for individuals with brain amyloidosis at both PiB cutoffs. Age and APOE genotype were the most useful and efficient indicators of PiB positivity (amyloid accumulation). However, the discrimination was modest, and the efficiency might come at the expense of narrowing the population of the labeling granted by a regulatory agency. Screening on subjective memory (in particular) and a positive family history would still improve efficiency, albeit more modestly than APOE and old age, with a minimal effect on regulatory labeling restrictions. Notably, many of these characteristics vary by age so it will be important to consider the age range of the population to optimally reduce screening costs when planning for a clinical trial.
There are currently no disease-modifying treatments for AD dementia. Although it could be that the right molecular target has yet to be identified, another ominous possibility is that the downstream pathophysiologic events dominate in the fully symptomatic stage and cannot be halted by anti-amyloid intervention alone. 19 AD pathophysiology begins to appear in the brain years before the clinical symptoms become apparent. This long preclinical phase provides a critical opportunity for the prevention of future symptoms with disease-modifying therapies. 20 Brain amyloid accumulation is considered the earliest pathologic feature of AD that is detectable by currently available biomarkers 3, 5, 8, 21 and is described as stage 1 by the new National Institute on Aging-Alzheimer's Association research criteria for preclinical AD. 8 Indeed, both postmortem and epidemiologic studies report that 20%-40% of CN elderly individuals have significant amyloid accumulation. [9] [10] [11] 18 Since cerebral amyloidosis is necessary, albeit not sufficient, for an AD diagnosis, and increases the risk of conversion to mild cognitive impairment, [22] [23] [24] [25] [26] [27] secondary prevention trials are now being designed that require documentation of brain amyloidosis for enrollment. 4 This requires an expensive amyloid PET scan or an in- vasive lumbar puncture for CSF amyloid levels. The identification of noninvasive, low-cost measures that would reduce the number of subjects needed to be screened with brain scans or lumbar punctures would greatly improve the efficiency of clinical trials targeting the preclinical disease phase. The literature examining the relationship between cognitive performance and brain amyloidosis has been inconsistent. Some studies show a crosssectional correlation between cognitive performance, particularly memory, 28 -30 while others do not find an association. [31] [32] [33] The logical conclusion is that the association exists, but is fairly weak. In the present study, better performance across all tests and domains was associated with reduced odds of PiB Ͼ1.4 and Ͼ1.5. However, the discrimination of each test was modest (AUROC ϳ0.6) and the global z score was similar to tests of delayed memory recall in indicating PiB positivity. Moreover, subjective memory complaints were as good of a predictor of PiB positivity as cognitive test performance, especially for PiB Ͼ1.5. Thus, extensive cognitive testing of CN elderly individuals with a standardized test battery may not be a costeffective screening tool for PiB positivity. While it is possible that other cognitive tests could be more sensitive, our full battery included assessments of all domains with an emphasis on delayed memory recall.
As expected, the presence of an APOE 4 allele was associated with 3-fold increased odds of PiB Ͼ1.4 and Ͼ1.5. Requiring the presence of an 4 allele for enrollment into a trial of preclinical AD could be helpful as a screening measure, and in restricting enrollees to those most likely to progress to clinical symptoms. A blood draw for APOE genotype is noninvasive and low-cost. However, selecting subjects based on APOE genotype would exclude a large portion of individuals at risk for AD who do not have an 4 allele. 34 From a regulatory perspective, additional studies in non-4 carriers would also be necessary. Thus, the findings that prescreening on the easily obtainable and cost-effective information of age, sex, family history of dementia/AD, and selfreported memory (all of which can be assessed over the phone) will still reduce the number of individuals needed to screen for brain amyloidosis is significant.
Notably, while screening on these factors will help reduce the costs of identifying individuals with amyloidosis, the NPVs (60%-70%) are modest. Thus, a number of individuals with amyloidosis, defined by either cutpoint, will screen negative and thus be excluded from the trial. While this may be concerning, the costs of screening and excluding the false negatives are minimal compared to screening all potential individuals with amyloid imaging or a lum-bar puncture for CSF to identify eligible individuals. Clearly, screening with these factors would not be an acceptable option for determining AD pathology in the clinical practice setting. However, from a clinical trial standpoint, it would greatly reduce the costs of identifying individuals with amyloidosis for AD prevention trials. Notably, the results for both cutoffs of PiB Ͼ1.4 and Ͼ1.5 were similar. This suggests that a cutoff of PiB Ͼ1.4 is biologically relevant and could be incorporated into preclinical AD trials.
Strengths of this study include a large sample size of individuals with PiB-PET recruited from the population-based MCSA. While participants with a PiB-PET scan were younger and performed slightly better on cognitive tests, the percentage of individuals in the MCSA with an APOE 4 allele or a family history of dementia/AD did not differ in those who participated in PET scanning compared to the whole MCSA population (table 1) . This is an advantage over most biomarker studies, which are not representative of the general older population. That is, volunteer cohorts typically have higher rates of family history and APOE 4 genotypes and tend to come from highly educated and higher socioeconomic status backgrounds. A potential limitation of the study is that findings from the residents of Olmsted County may not precisely generalize to other populations. In particular, Olmsted County residents are primarily of European ancestry, thus the reported estimates may differ in other ethnic groups.
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